BeStock  
Stocks › Biotechnology › SYRE

Spyre Therapeutics SYRE

US equityMarket cap rank #1512Biotechnology
$93.47 −$4.16 (-4.26%)
Market closed · Nov 22, 5:50 am ET · Last extended-hours $93.47 0.00%
Open$95.93
Prev close$97.63
Day range$93.22 – $99.56
Volume805.4K
Market cap$8.88B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-37.4x
CheapRich

Near the bottom of its 5-year range · 8th percentile, 5-year average -8.6x

Price / book10.9x
CheapRich

Near the top of its 5-year range · 94th percentile, 5-year average -56.4x

#4977 of 5331 stocks by PB (1 = cheapest)

Price / sales14,355.8x
CheapRich

Near the top of its 5-year range · 100th percentile, 5-year average 2,352.5x

#5145 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-59x-36x-13x10xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$105.87
Price vs. fair value-11.7%Trading below the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyHigh
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 10.91 – -56.40 94% (pricier than usual) #4977 of 5331 (1 = cheapest)
PE -37.41 -24.16 -8.58 8% (cheaper than usual) –
PS 14,355.81 – 2,352.49 100% (pricier than usual) #5145 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on SYRE.

Sign in to join the discussion.

Scroll to Top